Comparative Bioavailability Study Between Ticagrelor and ASA Administered Individually or in Combination.

Phase 1 Completed 24 enrolled Laboratorios Silanes S.A. de C.V.

RandomizedCrossoverOpen-labelTreatment

Summary

Study conducted to determine and compare the relative bioavailability of two solid oral formulations (reference versus test) of the non-fixed combination of Ticagrelor 90 mg (Brilinta by AstraZeneca S.A. de C.V.) + Acetylsalicylic Acid 100 mg (ASPIRINA JUNIOR by Bayer de México S.A. de C.V.) administered concomitantly versus the fixed-dose combination of Ticagrelor 90 mg / Acetylsalicylic Acid 100 mg manufactured by Laboratorios Silanes S.A. de C.V.

Timeline

Start: 2025-01-13
Primary completion: 2025-01-23
Completion: 2025-02-05

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Aspirin	Small molecule	100 mg	Oral
Subject	Ticagrelor	Small molecule	90 mg	Oral

Indications

No indication recorded.